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ARTICLE DATA

According to statistical data published in 2019, breast cancer is among the
leading causes of death in women worldwide. The serine/threonine kinase
(AKT) or protein kinase B (PkB) signaling pathway is activated by
phosphorylation processes, which further is associated with cell growth,
proliferation, and survival, but also with activation of glucose metabolism.
Mutations of the AKT signaling pathway components (especially PI3KCA
and PTEN) have been observed in breast cancer patients, which are
associated with resistance to hormonal treatment. Many clinical trials are
testing the effect of AKT inhibition in order to block the growth and
proliferation of breast cancer cells. The purpose of this review is to present
the incidence of this neoplastic disease, to describe AKT signaling
pathways activation, mutations that occur at its level, and inhibitors that
can block this protein kinase.

Introduction
Following a systemic analysis conducted over a period
of 27 years (1990-2017) regarding the incidence of
cancer, published online in September 2019, there were
24.5 million cases and 9.6 million deaths registered
worldwide [1]. Skin, breast, and colorectal cancer were
the most common neoplastic disorders reported among
women, representing 54% of all cancers [1]. In the Global
top 10 cancers, breast cancer was the third most common
cancer overall, with 2 million incident cases registered in
2017. Of the 143 countries that participated in the
systemic analysis, in 112 countries breast cancer was the
most common cause of death among women [1].
According to statistical data from Romania, the
incidence of neoplastic diseases in 2018 registered at
83,461 cases for both sexes, with 50,902 deaths [2]. In
Romanian women, the 5 most common types of cancer are
breast, colorectal, cervix uteri, lung, and corpus uteri. In
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2018, 38,439 cases of cancer were diagnosed in women, of
which 9625 were breast cancer [2]. Last year, Romania
registered 30,100 deaths among men and 20,200 among
women. In the case of women of Romanian origin, as well
as in other countries, breast cancer represents the most
common neoplastic disease, with 8,981 cases reported.
Breast palpation and clinical breast examination are
the classic methods available to all women for detecting
tumors, as mammography is not generally available at the
public health care level in many areas [3].

Discussions
Breast cancer subtypes
Currently, for a more accurate diagnosis of breast
cancer, a number of factors have been proposed, such as
tumor size and degree, histological subtype,
lymphovascular invasion of tumor cells, presence of
tumor cell receptors, and axial lymph nodes.
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Ki-67 is currently used as a valuable parameter that
expresses the potential for proliferation and division of
tumor cells. By combining genetic tests with histological
analyses
(macroscopic
and
microscopic)
and
immunohistochemistry, it is possible to detect the presence
of cell surface receptors [estrogen, progesterone, and
human epidermal growth factor receptor 2 (HER2)] [4].
Luminal A, Luminal B with HER 2 negative, Luminal
B with Her 2 positive, HER 2 enriched, and basal-like
(triple negative) are the most recent classifications (in
2013) for breast cancer, according to the St Gallen
classification system (Table 1) [4].
Table 1. According to St. Gallen classification [adapted
from 4-7]
Breast
cancer
subtypes

ER / Pr

HER 2 Ki67

Luminal A +and or/- -

Mutated genes Treatment

<14% PIK3CA(45%) Endocrine
therapy
AKT1(4%)
PTEN(4%)
≥14% PIK3CA (29%) Endocrine
therapy±
chemotherapy
Any
PIK3CA (29%) Chemotherapy
ki-67
+ anti+HER2
therapy+endoc
rine therapy

Luminal B + and
and HER or/negative

-

Luminal B + and
and HER or/positive

+

HER-2enriched

-/-

+

Any
ki-67

PIK3CA (39%) Chemotherapy
+ anti+HER 2

Basal-like -/(triple
negative)

-

-

PIK3CA (7%) Chemotherapy

Pi3k signaling pathway
Phosphatidylinositol-3 kinases (PI3K) are a family of
lipid structure kinases involved in the regulation of
numerous biological processes, such as cell proliferation,
survival and differentiation, metabolism, and migration
[8]. Depending on their structure and kinetic differences,
these protein kinases can be divided into 3 classes: class I,
II, and III. PI3Kα, PI3Kβ, PI3KŸ and PI3K چbelong to
class I and are unfortunately abnormally activated in
breast cancer [9]. These kinases contain a regulatory
subunit and a catalytic subunit, so for class IA, there are 3
catalytic subunits (p110α, p110β, p110 )چthat are encoded
by PIK3CA, PIK3CB, PIK3CD. The regulatory subunits
of class IA, p85α, p85β and p55Ÿ, are encoded by
PIK3R1, PIKR2 and PIKR3 [8, 9]. In the case of IB class
of protein kinases, which are heterodimers, the catalytic
subunit p110Ÿ is encoded by PIK3CG, presenting one or
two regulatory subunits, namely p101 encoded by
PIK3CR5 or p87 encoded by PIK3R6 [10]. All cell types
express the catalytic subunits p110α and p110β, while
p110Ÿ and p110 چare expressed only by leukocytes [10].
Class I PI3Ks are recruited to the plasma membrane
when the activator binds to the specific receptor, so the

catalytic subunit phosphorylates phosphatidylinositol 4,5
bisphosphate (PIP2) to phosphatidyl inositol 3,4,5
triphosphate (PIP3). PIP3 acts as a secondary messenger
and coordinates AKT localization at the plasma membrane
and then phosphorylation by PDK1 (phosphoinositide
dependent protein kinase-1) [10]. PDK1 phosphorylates
AKT at threonine residue 308, and for complete activation,
serine residue 473 is phosphorylated by mTOR
(mammalian target of rapamycin) [10,11].
mTOR is a serine / threonine protein kinase complex
that is composed of mTORC 1 and mTORC 2, these
having similar structure but different functions. mTORC2
phosphorylates AKT for full activation at serine.
Following activation by phosphorylation of AKT, this
protein kinase phosphorylates and thus inhibits tuberous
sclerosis complex 1 and 2 (TSC 1 and 2), this inhibition
leading to the activation of mTORC1. Once activated
mTORC1, it activates in turn 40 S ribosomal protein S6
kinase (S6K) and eukaryotic initiation factor 4E binding
protein (4EBP1) which lead to cell growth and activation
of glucose metabolism [12,13].
Phosphatase and tensin homolog (PTEN) negatively
regulate AKT by dephosphorylating PIP3 to PIP2. Apart
from PTEN, it has recently been observed that there may
be another negative regulator for PIP3, polyphosphate 4phosphatase type II (INPP4B) [14].

AKT activation in cancer
The incidence of mutations that occur in the AKT
signaling pathway in breast cancer is 25%. Most of these
mutations are found in the PIKCA that encodes the p110α
catalytic subunit, with the substitution of a single amino
acid such as E545K and E542K in the helical domain
(exon 9) and H1047R in the kinase domain (exon20) [15].
Mutations occurring both in the helical and kinase
domains will increase the enzymatic activity, of components
of AKT signaling pathways, which will promote oncogenic
transformation. Depending on the breast cancer subtype,
AKT mutations occur around 20-25% [16].
An increase of the mutations of over 30% is registered in
the case of the tumor that has hormonal receptors, for
HER2+, is registered 25% AKT mutations. In contrast, triple
negative breast cancer has the lowest rate of AKT mutations
[16]. A number of somatic gene mutations have already been
observed within this signaling pathway, including PI3CA,
PIKR1, PTEN, AKT1, which will result in either increased
PI3K activity or loss of PTEN functionality [16].
In mammals, class 1 protein kinases are divided into
1A and 1B, the first class being activated by tyrosine
kinase receptor (RTKs), and the second class by receptors
coupled with G proteins.
35
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The involvement of PI3K/ AKT signaling pathways in
breast cancer pathogenesis can be achieved through
several mechanisms:
1.

2.

3.
4.

The occurrence of mutations or amplification of
PI3KCA, PIK3CB, PIK3R1 leads to increased
activity of AKT signaling pathways.
Overexpression of some target molecules or
activating signals such as HER 2, epidermal growth
factor receptor (EGFR) , insulin-like growth factor
receptor 1(IGF-R1).
Loss of negative regulators for PIP3, PTEN and
INPP4B.
Overexpression of AKT1, AKT2 and PDK1 [16].

In breast cancer, the most common mutations of AKT
which determine the overactivation of this signaling
pathway are the loss of the negative PTEN regulator and
the PIK3CA mutation [17]. These changes cause cell
transformation, progression, and chair formation of the
tumor mass. In 2004, PIK3A, which encodes the p110α
catalytic subunit, was discovered to be the most common
genetic mutation being considered a highly oncogenic
gene [17]. Other mutations have been identified, for
example, in the kinase domain H1047R, in the catalytic
domain E542K and E545K [16]. She and co-workers
identified a 25% reduction for PTEN in breast cancer; the
same team of researchers observed in the case of triple
negative breast cancer, characterized by a low survival
rate, alteration with 30% of PTEN [18].

Endocrine resistance and PI3K/AKT
Mutations in AKT signaling pathways may be
responsible for resistance to hormonal treatment.
Hyperactivation of receptors such as HER1, HER2,
EGFR via AKT may contribute to the resistance of antiestrogen therapy [19].
Several mechanisms have been described as
responsible for endocrine resistance in breast cancer, such
as disorders of the ER/PgR pathway components,
modifications of signaling molecules involved in the cell
cycle or survival, or activation of signaling pathways that
ensure cell replication [20]. ER is composed of 2
subunits, namely ERα and ERβ, being a nuclear receptor.
Estrogen activation of ERα is responsible in many types
of breast cancer for cell proliferation. In contrast, ERβ
exhibits opposite effects of ERα, inhibiting the
stimulatory effects of estradiol (E2) on cell proliferation.
Alpha and beta receptors contain two transcriptional
domains, namely AF1 and AF2, both of which have
activation functions [21]. Binding of E2 to the ER leads to
the activation of a number of processes that result in the
translocation of chaperone proteins from the ERα
36

receptor, receptor dimerization, phosphorylation and
finally the binding of ER to DNA [22].
AF1 regulates gene transcription, even in cells that
exhibit ERα deletion, being independent of ligand, AF2
instead binds to coactivators or corepressors [23].
Activation of AF1 is mediated by crosslinks and crosstalk
among the RAS/B-RAF, AKT and CDK2 (cyclindependent kinase 2/7) pathways. This activation
mechanism unfortunately leads to resistance observed in
different endocrine therapies [24]. At the molecular level,
estrone activity leads to activation of insulin-like growth
factor (IGF), AKT, and MAPK signaling pathways. This
activation will downregulate ER and PgR expression at
the cell surface level [25].
In the case of metastatic breast cancer, the AKT
signaling pathway is most frequently altered, upregulation
of this molecules promotes the transcriptional activity of
ER that will contribute to anti-estrogen resistance, leading
to tumor growth, motility, metabolism and survival [26].

Breast cancer biomarkers and therapy
Currently, a number of AKT signaling pathway
inhibitors are being studied, which generally focus on the
simultaneous blocking of PI3K and mTOR. As already
noted, there is a link between increased activity of PI3K
and breast cancer tumorigenesis or drug resistance. Recent
studies have revealed the importance of testing and using
PI3K inhibitors in the tumor microenvironment [27].
Beneficial effects of PI3K inhibition have been
observed in the treatment of leukemia, improving
immunotherapy in solid cancer where it selectively blocks
T cell-mediated immune tolerance [28]. For example,
agent EL147 is a PI3K selective inhibitor that can block
IPI3K class. This drug, which can be administered orally,
cannot inhibit mTOR but a preclinical efficacy has been
observed on PI3K and PTEN. Among the first drugs that
were studied were those that were analogues of
rapamycin, so mTOR inhibition may play a crucial role in
the therapy of breast cancer. In a phase II randomized
trial, patients diagnosed with breast tumors > 2cm ER+
received letrozole plus placebo for 16 weeks or letrozole
and everolimus (rapamycin analog).
The administration of everolimus had a better
response rate to treatment. The use of mTOR inhibitors
has beneficial effects in breast cancer therapy [29].
Breast cancer classification is currently performed
according to histological evaluation, immunohistochemistry
and genetic testing, and biomarker detection can be of real
use in the most accurate diagnosis of this neoplastic disease.
Increased expression of cytokeratin 5/6 and 17, laminin, and
fatty acid binding protein was observed in basal-like tumors.
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These biomarkers show a 15% increase in invasive cancers,
being associated with breast cancer and BRCA
mutations [30].
Depending on the molecular classification, Luminal A
is a hormone receptor-positive breast cancer (estrogen
receptor and / or progesterone receptor positive), HER2
negative, and is associated with low levels of Ki-67 protein,
which helps in rapid growth of cancer cells. Luminal A
breast cancer has a lower degree, the proliferation rate is
slow, and it has the best prognosis. Luminal B breast
cancer is positive for hormone receptors (estrogen receptor
and / or progesterone receptor positive) and HER2 positive
or HER2 negative, associated with increased Ki-67 levels.
The rate of proliferation of Luminal cancer B is faster than
Luminal A breast cancer [30].
Negative/ basal triple breast cancer is the type of
neoplasia without hormonal receptors (estrogen receptor
and progesterone receptor negative) and HER2 negative.
It unfortunately develops in women with BRCA1 gene
mutations, among younger and African-American
women. HER2-enriched breast cancer is hormone
receptor negative (estrogen and progesterone) and HER2
positive. These cancers have a faster proliferation rate
than Luminal breast cancers and a poorer prognosis,
although they may be successfully treated with therapies
targeting the HER2 protein, such as Herceptin
(trastuzumab), Perjeta (pertuzumab), Tykerb (lapatinib)
and Nerlynx (neratinib) [30].
pS6K (S6 kinase) and pAKT are biomarkers of
response to inhibitors for mTOR pathway (rapamycin
analogues), tested on cell lines and tumors. Increased
levels of pS6K are associated with a reserved survival
prognosis [30]. Increased levels of phosphorylated
proteins such as AKT, GSK3β, and TSC2 have been
observed in various tumor cell lines [31].
INPP4B is a potential tumor suppressor biomarker that
regulates AKT, so deletion of this phosphatase results in
PTEN loss that will correlate with poor survival prognosis
[31-33].
An inhibitor of mTORC 1, everolimus was tested on
breast cancer cell lines that had the PIKCA mutation
where mTORC1 inhibition could be observed [31].
Ribosomal S6 kinases (RPS6KA2) and S4 (RSK4)
and c-myc activation are mutations of the mitogenactivated protein kinase signaling pathways (MAPK) that
may be the key of resistance to AKT inhibitors. Positive
effects have been reported for basal-like triple negative
breast cancer where inhibitors for AKT and MAPK have
been used [31].

Highlights
✓ Mutations of the AKT signaling pathway components
(especially PI3KCA and PTEN) have been observed
in breast cancer patients, which are associated with
resistance to hormonal treatment.
✓ Mutations that occur at this signaling pathway cause
AKT overactivation which will further lead to the
activation of target molecules responsible for cell
growth, survival and proliferation and protein
synthesis of breast tumor cells.

Conclusions
AKT is an extremely complicated intracellular
signaling pathway that has an important role in the
pathogenesis of breast cancer. Mutations that occur at this
signaling pathway cause AKT overactivation which will
further lead to the activation of target molecules
responsible for cell growth, survival, and proliferation and
protein synthesis of breast tumor cells.
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